Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.

Chen, Chun-Hsien

Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. [electronic resource] - Scientific reports 05 2019 - 7086 p. digital

Publication Type: Journal Article; Multicenter Study

2045-2322

10.1038/s41598-019-43554-3 doi


2-Naphthylamine
Aged
Anilides--adverse effects
Antiviral Agents--therapeutic use
Carbamates--adverse effects
Cyclopropanes
Drug Therapy, Combination
Female
Genotype
Hepacivirus--genetics
Hepatitis C, Chronic--complications
Humans
Lactams, Macrocyclic
Liver Cirrhosis--complications
Macrocyclic Compounds--adverse effects
Male
Middle Aged
Proline--analogs & derivatives
Retrospective Studies
Ribavirin--adverse effects
Ritonavir--adverse effects
Sulfonamides--adverse effects
Sustained Virologic Response
Uracil--adverse effects
Valine